Acute Intracranial Hemorrhage clinical trials at UC Irvine

• Trial of Andexanet Alfa in ICH Patients Receiving an Oral FXa Inhibitor

  open to eligible people ages 18 years and up

  Randomized, controlled clinical trial evaluating the efficacy and safety of andexanet alfa versus usual standard of care in patients with intracranial hemorrhage anticoagulated with a direct oral anticoagulant

  Orange, California and other locations

Last updated: October 27, 2021